Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.
PLoS One
; 17(8): e0273340, 2022.
Article
in En
| MEDLINE
| ID: mdl-36001576
Full text:
1
Database:
MEDLINE
Main subject:
COVID-19 Drug Treatment
Type of study:
Observational_studies
Limits:
Adult
/
Humans
Language:
En
Journal:
PLoS One
Journal subject:
CIENCIA
/
MEDICINA
Year:
2022
Type:
Article
Affiliation country:
RUSSIA